Abstract-All of the components of a complete dopamine system are present within the kidney, where dopamine acts as a paracrine substance in the control of sodium excretion. Dopamine receptors can be divided into D 1 -like (D 1 and D 5 ) receptors that stimulate adenylyl cyclase and D 2 -like (D 2 , D 3 , and D 4 ) receptors that inhibit adenylyl cyclase. All 5 receptor subtypes are expressed in the kidney, albeit in low copy. Dopamine is synthesized extraneuronally in proximal tubule cells, exported from these cells largely into the tubule lumen, and interacts with D 1 -like receptors to inhibit the Na ϩ -H ϩ exchanger and Na ϩ ,K ϩ -ATPase, decreasing tubule sodium reabsorption. During moderate sodium surfeit, dopamine tone at D 1 -like receptors accounts for Ϸ50% of sodium excretion. In experimental and human hypertension, 2 renal dopaminergic defects have been described: (1) decreased renal generation of dopamine and (2) a D 1 receptor-G protein coupling defect. Both defects lead to renal sodium retention, and each may play an important role in the pathophysiology of essential hypertension. (Hypertension. 2001;38:297-302.) Key Words: receptors, dopamine Ⅲ sodium excretion Ⅲ blood pressure Ⅲ cell signaling D opamine is a catecholamine serving 2 important roles in neurobiology: (1) as an intermediate in the biochemical pathway from the amino acid tyrosine to norepinephrine and epinephrine and (2) as a direct neurotransmitter in its own right. In neurons, dopamine is synthesized by the initial hydroxylation of tyrosine (tyrosine hydroxylase) to L-dihydroxyphenylalanine (L-DOPA) followed by decarboxylation to dopamine (aromatic amino acid decarboxylase). The central neurotransmitter role of dopamine in the regulation of motor function and behavior is well established. More recently, dopamine has been recognized as an important peripheral hormone modulating renal sodium excretion and blood pressure by its cell-to-cell actions within the kidney. 1 The present article reviews evidence for autocrine and paracrine actions of dopamine formed within the kidney, their cellular signaling pathways, and the potential role of dopamine in the pathophysiology of hypertension.
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Renal Dopamine Formation and Secretion
Although the classical pathway for dopamine biosynthesis occurs in neurons, in the kidney dopamine is synthesized independently of nerve activity. Dopamine excreted in urine is almost exclusively derived from intrarenally formed dopamine. 2 Dopamine is formed in large quantities in proximal tubule cells as a result of uptake of filtered L-DOPA via a sodium transporter in the apical membrane. 3 Inside the proximal tubule cell, L-DOPA is rapidly decarboxylated to dopamine by aromatic amino acid decarboxylase, the activity of which is upregulated by high-sodium diet and downregulated by low-salt diet. 4 Essentially nothing is known about the mechanisms by which dopamine is stored in the proximal tubule cell. Dopamine is catabolized in the kidney mainly by catechol-o-methyl-transferase and monoamine oxidase A. 5, 6 Dopamine can exit the cell at either the apical or the basolateral surface. The basolateral outward transporter is dependent on sodium and pH and is developmentally regulated, but little is known about apical dopamine secretion. 7 The supply of L-DOPA to the proximal tubule is an important determinant of the amount of dopamine formed and secreted. L-DOPA or ␥-L-glutamyl-L-DOPA (gludopa), a dopamine prodrug, markedly increases urinary dopamine excretion. 2 However, the outward transport of dopamine from the proximal tubule cell in vivo is preferentially directed to the tubule lumen rather than across the basolateral surface into the peritubular space, as the increase in urinary dopamine far exceeds the increment of dopamine in the renal interstitial space. 8 These observations suggest that dopamine is highly compartmentalized within the kidney. Certainly, dopamine accessibility to its receptors determines functional changes in the control of sodium excretion and blood pressure.
The intrarenal production of dopamine is not significantly modulated by renal sympathetic nerve activity, as chronic renal denervation does not affect basal or gludopa-stimulated renal dopamine. 8 -10 A schematic representation of proximal tubule cell biosynthesis, release, and action of dopamine is presented in Figure 1 . Both the D 1 -like and D 2 -like receptor families are expressed in the kidney at postjunctional sites. The D 1 receptor (and probably also the D 5 receptor) is localized in the smooth muscle layer of renal arterioles, juxtaglomerular cells, proximal tubules, and the cortical collecting duct both by immunohistochemistry and by in situ amplification of mRNA. [12] [13] [14] The D 3 receptor is present in arterioles, glomeruli, proximal tubules, mTAL cells, and the cortical collecting duct by immunohistochemistry. 15 The D 4 receptor is localized to the cortical collecting duct. 16 
Dopamine Regulation of Renal Sodium Excretion
The D 1 -like receptor family plays a major role in the regulation of tubule sodium reabsorption. Numerous studies have demonstrated that dopamine induces a large increase in urinary sodium excretion that is dependent on inhibition of tubule sodium reabsorption. The natriuretic action of dopamine, which is due to inhibition of both proximal and distal tubule sodium absorption, was first demonstrated in studies in which the selective D 1 -like receptor agonist fenoldopam was administered. [17] [18] [19] This effect was distinct from the renal vasodilator action of exogenous dopamine that depended on increased concentrations of circulating dopamine. 20 Since 1988, many additional studies have confirmed that the administration of dopamine engenders natriuresis by inhibiting tubule sodium reabsorption. The natriuretic effect of intrarenal dopamine was first observed after administration of the dopamine prodrug gludopa. Gludopa is devoid of pharmacological activity per se but is converted to L-DOPA and then to dopamine by sequential actions of the brush border enzyme ␥-glutamyl transpeptidase and cytosolic L-aromatic amino acid decarboxylase (LAAD) in proximal tubule cells, where both enzymes exist in abundance. 21 Earlier studies had shown significant natriuresis and renal vasodilation with pharmacological quantities of gludopa. [22] [23] [24] However, administration of physiological quantities of gludopa was accompanied by a significant natriuresis with no detectable change in intrarenal blood flow, indicating a predominantly tubule effect. 8 During conditions of normal sodium balance, endogenous intrarenal dopamine is a major physiological regulator of urine sodium excretion. Studies employing a specific D 1 -like receptor antagonist (SCH-23390) in both anesthetized and conscious animals have demonstrated that Ϸ50% of basal sodium excretion is controlled by dopamine. [25] [26] [27] Conclusive evidence was provided that renal dopamine acts at the tubule to control sodium excretion. 26 Administration of SCH-23390 at low infusion rates directly into the renal artery (confined to the kidney during the experimental period) engendered a dose-dependent antinatriuresis that was reversible on cessation of infusion. No changes in renal blood flow (RBF) or glomerular filtration rate (GFR) were observed. These studies were the first to show that dopamine acts as a paracrine substance, locally modulating renal sodium excretion. The ability of renal dopamine to control sodium excretion may be lost during hydropenia, sodium restriction, or marked sodium loading. 19, 25, 26, 28 A recent study provided direct evidence for a natriuretic effect of endogenous renal dopamine. 29 By infusing rats with antisense oligodeoxynucleotides directly into the renal interstitial space, the expression of D 1A receptor protein was reduced by 35% to 46% without influencing D 1B (D 5 ) receptors. This procedure decreased urinary sodium excretion during both normal and high sodium intake. The antinatriuresis was transient in spite of continued inhibition of D 1A receptor protein expression. 29 Because the D 1 receptor has been shown to stimulate renin secretion, the D 1A receptor knockdown may have inhibited renin secretion sufficiently to overcome the antinatriuretic action of decreased D 1 receptor expression. 30 However, this action on renin secretion may have been counterbalanced by an upregulation of angiotensin type 1 (AT 1 ) receptors, because dopamine also reduces AT 1 receptor mRNA. 31 Recently, some evidence also has been presented indicating that the D 3 receptor may play a role in the control of renal function. The selective D 3 receptor agonist, (Ϯ)-7-hydroxy-2-(di-n-propyl-amino)tetralin increased GFR and decreased RBF, an effect abolished by selective D 3 receptor antagonist U-99194A but not by the D 2 receptor antagonist sulpiride 32 These data indicated that D 3 receptor activation may increase GFR by postglomerular (efferent) arteriolar constriction. Furthermore, a D 2 -like receptor, possibly D 4 , in the basolateral membrane appears to be responsible for the natriuretic action of dopamine in the cortical collecting duct. 33 
Cell Signaling Pathways
The major cell signaling pathways of renal dopamine are depicted in Figure 1 . A major signaling mechanism whereby renal dopamine induces natriuresis is by its inhibition of Na ϩ ,K ϩ -ATPase. 34 -36 Dopamine inhibits Na ϩ ,K ϩ -ATPase in the entire nephron, including the proximal tubule, the thick ascending limb of Henle, the distal tubule, and the cortical collecting duct. [37] [38] [39] [40] [41] The dopamine receptor(s) responsible for the regulation of Na ϩ ,K ϩ -ATPase activity are currently unresolved. In general, D 1 -like receptors inhibit, whereas D 2 -like receptors stimulate, Na ϩ ,K ϩ -ATPase activity. However, D 2 -like receptors can act synergistically with D 1 -like receptors to increase sodium excretion by inhibition of Na ϩ ,K ϩ -ATPase. [42] [43] [44] [45] The cell signaling pathways whereby dopamine mediates inhibition of Na ϩ ,K ϩ -ATPase activity appear to be nephron specific. In the proximal tubule, both protein kinase A (PKA) and protein kinase C (PKC) are involved, whereas in mTAL and the cortical collecting duct only PKA is required. 42,43,46 PKC may inhibit Na ϩ ,K ϩ -ATPase activity also by stimulation of PLA 2 activity and the generation of 20-HETE by cytochrome P-450. 46 ,47 PKA and PKC mediate the phosphorylation of the catalytic subunit of Na ϩ ,K ϩ -ATPase, which directly inhibits its enzymatic activity. 48 Phosphorylation may also lead to internalization and inactivation of the enzyme. 49 A major component of the regulatory control of Na ϩ ,K ϩ -ATPase by dopamine may be the primary action of dopamine to inhibit the Na ϩ /H ϩ exchanger and the Na ϩ /P i cotransporter in the apical membrane of the tubule cell. As a result of this action of dopamine, intracellular Na ϩ is too low to stimulate Na ϩ ,K ϩ -ATPase activity. Dopamine inhibits sodium entry into tubule cells via its action at the D 1 -like receptor to inhibit sodium-hydrogen exchange (NHE) and Na ϩ /P i cotransport activation. 50, 51 On the other hand, D 2 -like receptors stimulate sodium entry by these mechanisms. The inhibitory action of dopamine on NHE is predominantly due to activation of cAMP and PKA. 50 Renal proximal tubule apical NHE activity also can be inhibited by D 1 -like receptors via G proteins directly, independently of cAMP and phosphorylation mechanisms. 52 Dopamine also can reduce NHE activity by stimulation of P-450 eicosanoids, such as 20-HETE. 46
Dopamine D 1 Receptor Sensitization and Desensitization
Studies of the cell membrane and cytosolic expression of the D 1 receptor have been greatly facilitated by the development of a highly specific antibody that recognizes the third extracellular loop of the receptor. 12 Under basal conditions, it was found that most of the D 1 receptors are located in the cytosol, not on the membrane, in both proximal tubule and cardiac myocytes. 12 In keeping with the concept that G proteincoupled receptors undergo a cycle of internalization and desensitization, the D 1 receptor has been shown to uncouple from its effector complex by a ligand-independent process of desensitization. 53 This process is thought to be related to phosphorylation of the receptor by one of the G proteincoupled receptor-related kinases (GRKs) resulting in their desensitization. The internalized receptors are packaged in vesicles and endosomes that have an acidic environment. It was assumed that the recycling of vesicles and endosomes and the insertion of the receptor into the cell membrane is an unregulated (constitutive) process. However, recent studies have demonstrated in proximal tubule cells that are exposed to dopamine or the D 1 -like receptor agonist fenoldopam that the agonist initiated recruitment of the D 1A receptor to the cell membrane. 54 This effect was abolished by an inhibitor of the vesicular H ϩ pump, requires agonist binding to the D 1 receptor, and is mediated by cAMP or cGMP. Thus, agonistspecific ligand binding to the receptor creates a positive feedback mechanism for sustaining a physiological response, such as stimulation of sodium excretion. The known mechanisms of dopamine receptor sensitization and desensitization are shown in Figure 3 .
Renal Dopamine and Hypertension
Over the years, it has become apparent that the common factor in the generation of hypertension in man and experimental animals is disruption of normal sodium excretion. Therefore, there has been much interest in the possible role of renal dopamine and of dopamine receptors in hypertension.
Two fundamental defects in the renal dopamine system have been described in hypertension: (1) deficient renal 
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Renal Dopamine, Sodium, and Blood Pressure 299 dopamine production due to reduced renal uptake and/or decarboxylation of DOPA 54, 55 and (2) defective D 1 -like receptor-G protein coupling such that renal dopamine is ineffective in transmitting a signal to inhibit sodium excretion. 11 Both defects may result in sodium retention and hypertension. A large body of evidence regarding the role of dopamine receptors in hypertension has accumulated from animal models in which the individual dopamine receptors have been disrupted. Disruption of the D 1 receptor in mice leads to the development of hypertension, but a mutation in the coding region of the D 1 receptor has not been found in human essential hypertension or in genetically hypertensive rats. 53, [57] [58] [59] Disruption of the D 2 receptor also leads to hypertension, but the increased blood pressure is related to increased noradrenergic discharge and is not associated with sodium retention. 60 Disruption of the D 3 receptor gene induces a renin-dependent form of hypertension, and these mice also cannot excrete a sodium load. 61 These results with whole body knockout of a dopamine receptor for a lifetime are informative, but compensatory mechanisms may alter the resulting phenotype. Additional value would be obtained by conducting renal-specific knockout of the dopamine receptors during adulthood, for example using antisense oligonucleotides for the dopamine receptors administered into 1 kidney via an adeno-associated vial vector.
Recently, a great deal of interest has been focused on the defect in D 1 receptor-G protein coupling in spontaneously hypertensive rats and Dahl salt-sensitive hypertensive rats. The first demonstration of such a coupling defect was made in 1989. 62 Subsequently, studies from many laboratories have confirmed and extended these observations. [63] [64] [65] [66] [67] [68] [69] This defect is present in human proximal tubule cells and is confined to the proximal tubule. 53 Studies now are beginning to point toward a possible defect in D 1 receptor-G protein complex recycling and recruitment of receptors to the cell membrane. Felder et al 53, 70, 71 reported that the D 1 receptor is hyperphosphorylated at the serine residue in renal proximal tubule cells from humans with essential hypertension and from spontaneously hypertensive rats. It is now thought that possibly one of the GRKs that phosphorylate and desensitize the receptor may be involved. In this regard, it is interesting that GRK activity was increased in the lymphocytes of patients with essential hypertension. 72, 73 On the other hand, there is some preliminary evidence that there may also be a defect in recruitment of the D 1 receptor to the cell membrane. 11, 73 Very few clinical studies have addressed the presence of a renal tubule D 1 receptor defect in human hypertension. Salt-sensitive hypertensive subjects were demonstrated to have a proximal tubule D 1 -like receptor defect similar to that of spontaneously hypertensive rats and Dahl salt-sensitive hypertensive rats. 74 Interestingly, however, there was upregulation of D 1 -like receptor function in the distal nephron, which offset the proximal tubule defect. 74 The compensatory inhibition of distal sodium reabsorption could be related to upregulation of D 1 -like receptors due to concomitant reduction in renal dopamine formation or simply to unopposed receptors in that nephron segment.
Physiological Analysis of a Dopaminergic Defect in Hypertension
In light of the present evidence (summarized above), it is likely that a substantial number of patients with essential hypertension may have a selective proximal tubule defect wherein there is absent D 1 receptor-G protein coupling, leading to increased proximal tubule sodium reabsorption, extracellular fluid volume expansion, and increased blood pressure ( Figure 4 ). This defect may be due to inactivation of D 1 receptors secondary to hyperphosphorylation, to defective receptor cycling, or both. The increase in blood pressure should cause a reduction in baseline proximal sodium reabsorption to normal via pressure natriuresis. The initial increase in proximal tubule sodium reabsorption should decrease distal tubule sodium delivery, which should decrease afferent arteriolar resistance, due to tubuloglomerular feedback mechanisms, leading to an increase in RBF and GFR. Decreased distal tubule sodium delivery also should increase renin secretion, which would not be expected to be entirely suppressed by the increase in blood pressure. Increased blood pressure would normalize both proximal and distal tubule sodium reabsorption, but at the expense of increased blood pressure.
The foregoing scenario would be expected to result in hypertension, normal baseline proximal and distal sodium reabsorption, normal (nonsuppressed) plasma renin activity, and increased GFR and RBF. In response to D 1 -like receptor agonist (eg, fenoldopam) administration at a dose that does not alter blood pressure, one would expect no reduction in proximal tubule sodium reabsorption, a major decrease in distal tubule sodium reabsorption due to "unopposed" or upregulated D 1 and D 5 receptors, and natriuresis. These are precisely the baseline and D 1 -like receptor agonist responses that have been demonstrated in patients with salt-sensitive hypertension. 74 Future studies addressing the specific dopamine receptor defect(s) in patients with genetic predisposition for salt-sensitive hypertension and in hypertensives themselves will be important to clarify the role of the renal dopamine system in the pathogenesis of hypertension. 55, 56, 62, 70, 71, 74 Physiology and Biophysics at Georgetown University, for their assistance in the preparation and review of the manuscript.
